9 Jul 2004

UCB has over 90% of Celltech Shares

Read More
24 Jun 2004

UCB Pharma* announces unique mode of action for Keppra ®

Read More
21 Jun 2004

UCB Pharma announces granting of European marketing authorisation for innovative transdermal therapy for symptomatic treatment of urge incontinence

Read More
8 Jun 2004

Annual General Meeting of UCB Shareholders

Read More
18 May 2004

Celltech and UCB Reach Worldwide Agreement on Development and Marketing of CDP870

Read More
18 May 2004

UCB S.A. launches a friendly offer to acquire Celltech Group plc, the leading UK-based biotech company

Read More
27 Apr 2004

UCB 44212, the second analogue of UCB Pharma’s anti-epileptic, KEPPRA*, enters clinical study phase

Read More
25 Mar 2004

UCB Group: confirmed increase of 2% in net results

Read More
22 Mar 2004

UCB Group : Keppra® Patent

Read More
6 Feb 2004

UCB Pharma announces partnership with Dynavax to develop and market products for the treatment of allergies

Read More
Subscribe to